Dose delay for grade 2 irAE

Vantrexa · Metastatic NSCLC

MI-2026-0522UrgentClosedWithin SLA

FAFatima Al-SayedMedical Information Lead

Received: 06 Aug 2026, 16:48 UTC
Channel: Email
Requestor type: Pharmacist
Country / region / team: Japan · Asia-Pacific · MI APAC
Category: Dosing
Response type: Standard response
Owner: FAFatima Al-Sayed
Due: 08 Aug 2026, 16:48 UTC
Responded: 07 Aug 2026, 10:48 UTC
Quality review: Not required
Related insight: —
Related standard response: SR-VTX-004 · Dose delay for grade 2 immune-related adverse events (v2)

Workflow

12-stage inquiry workflow (PRD §16). Advancing records an audit event.

Current stageClosedDemo action — not persisted

Urgent: 48 h target · Routine 120 h / Urgent 48 h / Critical 24 h

SLA hours

Elapsed

18 h

to response

Remaining

30 h

38%

06 Aug 2026, 16:48 UTC
Received via Email
Pharmacist · Japan
06 Aug 2026, 16:48 UTC
Triage and assignment
Urgency Urgent · assigned to MI APAC
07 Aug 2026, 10:48 UTC
Response sent
Standard response · quality review not required
08 Aug 2026, 16:48 UTC
SLA due (48 h)

Demo — drafts are not persisted

AI suggestion available for non-safety inquiries

Draft response

No audit events for this record

Create, update, approve and export events appear here with user, timestamp, previous and new values.

Data lineage: MI inquiry platform (IRMS, INT-05) · received 06 Aug 2026 · hourly sync.